SciVision Biotech : Announcement of the approval for recordation being granted by FSC on extended offering period of the second domestic unsecured convertible bonds
Announcement of the approval for recordation
being granted by FSC on extended offering period of the
second domestic unsecured convertible bonds
Date of events
2022/08/15
To which item it meets
paragraph 51
Statement
1.Date of occurrence of the event:2022/08/15
2.Company name:SciVision Biotech Inc.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:(1)The Company applied for extending the second
domestic unsecured convertible bonds each with a par value of NTD 100,000,
for a total amount of NTD 400,000,000.This application was approved by the
Financial Supervisory Commission per May 27, 2022 letter No.1110343177.
(2)On consideration of bigger fluctuation for domestic stock market and
better issuance timing, and following the board resolution on May 03,2022
regarding authorizing chairman to do revision when conducting the issuance
of domestic second unsecured convertible corporate bond responding to the
change of objective environment.
(3)Apply to the FSC for 3 months extension on August 11,2022 and looking
for the best time of offering the subscription payment in order to protect
shareholders' and investors' rights and interests. The request was granted
by the Financial Supervisory Commission in the letter No.1110352569 dated
August 15, 2022, and the filing period was extended to November 26, 2022.
6.Countermeasures:None
7.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
SciVision Biotech Inc. published this content on 15 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2022 10:12:09 UTC.
SciVision Biotech Inc is principally engaged in the manufacturing and distribution of hyaluronic acid medical supplies. The Company primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The Company is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The Company operates its business in the Americas, Europe, Asia, Middle East and Africa.
SciVision Biotech : Announcement of the approval for recordation being granted by FSC on extended offering period of the second domestic unsecured convertible bonds
SCIVISION BIOTECH INC. 
